{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:41:05Z","timestamp":1790707265671,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-025-02836-5","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T08:33:08Z","timestamp":1760085188000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study"],"prefix":"10.1186","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8375-7409","authenticated-orcid":false,"given":"Sema","family":"Hep\u015fen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"Haymana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bur\u00e7ak","family":"Cavnar Helvac\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halil","family":"Duranta\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bora","family":"Toros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramazan","family":"\u00c7akmak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"G\u00fcven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130brahim","family":"Demirci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lezan","family":"Keskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinem","family":"K\u0131y\u0131c\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehra Ya\u011fmur","family":"\u015eahin Alak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Sarg\u0131n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonca","family":"Tamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damla","family":"Balc\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berna \u0130mge","family":"Aydo\u011fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arzu","family":"Or Koca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Aydemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130lhan","family":"Tarkun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u0131nar","family":"K\u00f6ksal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayten","family":"O\u011fuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eda","family":"Demir \u00d6nal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00fcleyman","family":"Baldane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed","family":"K\u0131z\u0131lg\u00fcl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erman","family":"\u00c7akal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bekir","family":"\u00c7ak\u0131r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015eefika Bur\u00e7ak","family":"Polat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130lhan","family":"Yetkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emre","family":"Bozk\u0131rl\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcls\u00fcm","family":"Karaahmetli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevg\u00fcl","family":"Fak\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narimana Imanova","family":"Yaghji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ay\u015fin","family":"\u00d6ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burak","family":"\u00d6zba\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015eenay","family":"Topsakal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevde Nur","family":"F\u0131rat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayri","family":"Bostan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bar\u0131\u015f","family":"Karag\u00fcn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Okan Sefa","family":"Bak\u0131ner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ay\u015fe","family":"Karg\u0131l\u0131 \u00c7arl\u0131o\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahri","family":"Evren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kader","family":"U\u011fur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faruk","family":"K\u0131l\u0131n\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Batman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selin","family":"\u00c7akmak Demir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilek","family":"Yaz\u0131c\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O\u011fuzhan","family":"Deyneli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Metin","family":"Arslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omercan","family":"Topalo\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K\u00fcbra","family":"Kocatepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kemal","family":"Karag\u00f6zo\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakin","family":"Tekin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taner","family":"Bayraktaro\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibel","family":"Ertek Yal\u00e7\u0131n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ay\u015fe","family":"Kubat \u00dcz\u00fcm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6k\u00e7em Yal\u0131n","family":"Kocamaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehtap","family":"\u015eahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf","family":"Ayd\u0131n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Kutlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tevfik","family":"Sabuncu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Cesur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volkan Demirhan","family":"Yumuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahri","family":"Bayram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alper","family":"S\u00f6nmez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"2836_CR1","volume-title":"Obesity and overweight","author":"World Health Organization (WHO)","year":"2024","unstructured":"World Health Organization (WHO). Obesity and overweight. Geneva: World Health Organization; 2024."},{"key":"2836_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1159\/000455952","volume":"10","author":"JE Blundell","year":"2017","unstructured":"Blundell JE, et al. Variations in the prevalence of obesity among european countries, and a consideration of possible causes. Obes Facts. 2017;10:25\u201337.","journal-title":"Obes Facts"},{"key":"2836_CR3","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s10654-013-9771-5","volume":"28","author":"I Satman","year":"2013","unstructured":"Satman I, et al. Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. Eur J Epidemiol. 2013;28:169\u201380.","journal-title":"Eur J Epidemiol"},{"key":"2836_CR4","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1159\/000496183","volume":"12","author":"D Durrer Schutz","year":"2019","unstructured":"Durrer Schutz D, et al. European practical and patient-centred guidelines for adult obesity management in primary care. Obes Facts. 2019;12:40\u201366.","journal-title":"Obes Facts"},{"key":"2836_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.peptides.2017.12.009","volume":"100","author":"E Brown","year":"2018","unstructured":"Brown E, Cuthbertson DJ, Wilding JP. Newer GLP-1 receptor agonists and obesity-diabetes. Peptides. 2018;100:61\u20137.","journal-title":"Peptides"},{"key":"2836_CR6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1742-1241.2010.02499.x","volume":"64","author":"LB Knudsen","year":"2010","unstructured":"Knudsen LB. Liraglutide: the therapeutic promise from animal models. Int J Clin Pract. 2010;64:4\u201311.","journal-title":"Int J Clin Pract"},{"key":"2836_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer X, et al. A Randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373:11\u201322.","journal-title":"N Engl J Med"},{"key":"2836_CR8","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/oby.22726","volume":"28","author":"TA Wadden","year":"2020","unstructured":"Wadden TA, et al. Liraglutide 3.0 mg and intensive behavioral therapy (IBT) for obesity in primary care: the scale IBT randomized controlled trial. Obesity. 2020;28:529\u201336.","journal-title":"Obesity"},{"key":"2836_CR9","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/dom.13125","volume":"20","author":"MJ Davies","year":"2018","unstructured":"Davies MJ, et al. Liraglutide and cardiovascular outcomes in adults with overweight or obesity: a post hoc analysis from SCALE randomized controlled trials. Diabetes Obes Metab. 2018;20:734\u20139.","journal-title":"Diabetes Obes Metab"},{"key":"2836_CR10","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1002\/oby.22462","volume":"27","author":"S Wharton","year":"2019","unstructured":"Wharton S, et al. Real-world clinical effectiveness of liraglutide 3.0 mg for weight management in Canada. Obesity. 2019;27:917\u201324.","journal-title":"Obesity"},{"key":"2836_CR11","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1159\/000518325","volume":"14","author":"CL Haase","year":"2021","unstructured":"Haase CL, Serratore Achenbach MG, Lucrezi G, Jeswani N, Maurer S, Egermann U. Use of Liraglutide 3.0 mg for Weight Management in a Real-World Setting in Switzerland. Obes Facts. 2021;14:568\u201376.","journal-title":"Obes Facts"},{"key":"2836_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13399","author":"JJ Gorgojo-Mart\u00ednez","year":"2019","unstructured":"Gorgojo-Mart\u00ednez JJ, Basagoiti-Carre\u00f1o B, Sanz-Velasco A, Serrano-Moreno C, Almod\u00f3var-Ruiz F. Effectiveness and tolerability of orlistat and liraglutide in patients with obesity in a real-world setting: The XENSOR Study. Int J Clin Pract. 2019. https:\/\/doi.org\/10.1111\/ijcp.13399.","journal-title":"Int J Clin Pract"},{"key":"2836_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2024.108777","volume":"38","author":"SG Albert","year":"2024","unstructured":"Albert SG, Wood EM. FIB-4 as a screening and disease monitoring method in pre-fibrotic stages of metabolic dysfunction-associated fatty liver disease (MASLD). J Diabetes Complications. 2024;38: 108777.","journal-title":"J Diabetes Complications"},{"key":"2836_CR14","volume-title":"Obesity: preventing and managing the global epidemic","author":"World Health Organization","year":"2000","unstructured":"World Health Organization. Obesity: preventing and managing the global epidemic. Geneva: World Health Organization; 2000."},{"key":"2836_CR15","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S2213-8587(24)00182-7","volume":"12","author":"BM McGowan","year":"2024","unstructured":"McGowan BM, et al. Efficacy and safety of once-weekly semaglutide 2\u00b74 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial. Lancet Diabetes Endocrinol. 2024;12:631\u201342.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2836_CR16","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2024.2525","author":"PJ Rodriguez","year":"2024","unstructured":"Rodriguez PJ, et al. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA Intern Med. 2024. https:\/\/doi.org\/10.1001\/jamainternmed.2024.2525.","journal-title":"JAMA Intern Med"},{"key":"2836_CR17","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S0140-6736(24)00351-9","volume":"403","author":"Q Shi","year":"2024","unstructured":"Shi Q, et al. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. Lancet. 2024;403:e21\u201331.","journal-title":"Lancet"},{"key":"2836_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/cob.12594","author":"A Alshehri","year":"2023","unstructured":"Alshehri A, AlFaris N, Al Qahtani AM, Shams M, Yahia M. Clinical effectiveness of Liraglutide 3.0 mg and impact of weight loss in improving obesity-related comorbid conditions in King Fahad Medical City, Kingdom of Saudi Arabia: a real-world experience. Clin Obes. 2023. https:\/\/doi.org\/10.1111\/cob.12594.","journal-title":"Clin Obes."},{"key":"2836_CR19","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1007\/s40618-020-01334-1","volume":"43","author":"F Ferrari","year":"2020","unstructured":"Ferrari F, et al. Weight loss effect of liraglutide in real-life: the experience of a single Italian obesity center. J Endocrinol Invest. 2020;43:1779\u201385.","journal-title":"J Endocrinol Invest"},{"key":"2836_CR20","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/s41366-021-00739-z","volume":"45","author":"JH Park","year":"2021","unstructured":"Park JH, Kim JY, Choi JH, et al. Effectiveness of liraglutide 3 mg for the treatment of obesity in a real-world setting without intensive lifestyle intervention. Int J Obesity. 2021;45:776\u201386. https:\/\/doi.org\/10.1038\/s41366-021-00739-z.","journal-title":"Int J Obesity"},{"key":"2836_CR21","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/osp4.420","volume":"6","author":"S Wharton","year":"2020","unstructured":"Wharton S, et al. Weight loss and persistence with liraglutide 3.0 mg by obesity class in the real-world effectiveness study in Canada. Obes Sci Pract. 2020;6:439\u201344.","journal-title":"Obes Sci Pract"},{"key":"2836_CR22","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1159\/000520217","volume":"15","author":"L Trenson","year":"2022","unstructured":"Trenson L, et al. Liraglutide for weight management in the real world: significant weight loss even if the maximal daily dose is not achieved. Obes Facts. 2022;15:83\u20139.","journal-title":"Obes Facts"},{"key":"2836_CR23","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.3390\/metabo12111121","volume":"12","author":"J Silva-Nunes","year":"2022","unstructured":"Silva-Nunes J, et al. Liraglutide effectiveness in type 2 diabetes: insights from a real-world cohort of portuguese patients. Metabolites. 2022;12:1121.","journal-title":"Metabolites"},{"key":"2836_CR24","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.1111\/dom.15244","volume":"25","author":"F Giorgino","year":"2023","unstructured":"Giorgino F, et al. The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes (TROPHIES): Final, 24-month analysis of time to first significant treatment change, treatment persistence and clinical outc. Diabetes Obes Metab. 2023;25:3465\u201377.","journal-title":"Diabetes Obes Metab"},{"key":"2836_CR25","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41598-021-04149-z","volume":"12","author":"K Tanaka","year":"2022","unstructured":"Tanaka K, Okada Y, Tokutsu A, Tanaka Y. Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective study. Sci Rep. 2022;12:154.","journal-title":"Sci Rep"},{"key":"2836_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.935180","volume":"13","author":"Y Tan","year":"2022","unstructured":"Tan Y, et al. Association between use of liraglutide and liver fibrosis in patients with type 2 diabetes. Front Endocrinol (Lausanne). 2022;13: 935180.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2836_CR27","doi-asserted-by":"publisher","DOI":"10.1177\/08971900241253661","author":"M Wood","year":"2024","unstructured":"Wood M, et al. Impact of GLP-1 receptor agonist use in patients with steatotic liver disease and type 2 diabetes: a retrospective cohort study. J Pharm Pract. 2024. https:\/\/doi.org\/10.1177\/08971900241253661.","journal-title":"J Pharm Pract"},{"key":"2836_CR28","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1111\/dom.13672","volume":"21","author":"M Suliman","year":"2019","unstructured":"Suliman M, et al. Routine clinical use of liraglutide 3 mg for the treatment of obesity: Outcomes in non-surgical and bariatric surgery patients. Diabetes Obes Metab. 2019;21:1498\u2013501.","journal-title":"Diabetes Obes Metab"},{"key":"2836_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13811","author":"A Esparham","year":"2024","unstructured":"Esparham A, Mehri A, Dalili A, Richards J, Khorgami Z. Safety and efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists in patients with weight regain or insufficient weight loss after metabolic bariatric surgery: a systematic review and meta-analysis. Obes Rev. 2024. https:\/\/doi.org\/10.1111\/obr.13811.","journal-title":"Obes Rev"},{"key":"2836_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1043789","author":"L Liu","year":"2022","unstructured":"Liu L, Chen J, Wang L, Chen C, Chen L. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database. Front Endocrinol. 2022. https:\/\/doi.org\/10.3389\/fendo.2022.1043789.","journal-title":"Front Endocrinol"},{"key":"2836_CR31","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.33326","volume":"7","author":"H Gasoyan","year":"2024","unstructured":"Gasoyan H, Pfoh ER, Schulte R, et al. One-year weight reduction with semaglutide or liraglutide in clinical practice. JAMA. 2024;7: e2433326. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.33326.","journal-title":"JAMA"},{"key":"2836_CR32","doi-asserted-by":"publisher","DOI":"10.23736\/S2724-6507.24.04161-7","author":"C Tavares Bello","year":"2024","unstructured":"Tavares Bello C, et al. Liraglutide in the management of obesity: real world data (Portugal). Minerva Endocrinol. 2024. https:\/\/doi.org\/10.23736\/S2724-6507.24.04161-7.","journal-title":"Minerva Endocrinol"},{"key":"2836_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1364110","author":"KA Alenzi","year":"2024","unstructured":"Alenzi KA, Alsuhaibani D, Batarfi B, Alshammari TM. Pancreatitis with use of new diabetic medications: a real-world data study using the post-marketing FDA adverse event reporting system (FAERS) database. Front Pharmacol. 2024. https:\/\/doi.org\/10.3389\/fphar.2024.1364110.","journal-title":"Front Pharmacol"},{"key":"2836_CR34","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.pcd.2024.05.005","volume":"18","author":"GA Tagliapietra","year":"2024","unstructured":"Tagliapietra GA, Cantrell MA, Lund BC. Glucagon-like peptide receptor agonists and risk for depression. Prim Care Diabetes. 2024;18:422\u20136.","journal-title":"Prim Care Diabetes"},{"key":"2836_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-024-06243-z","author":"I Hurtado","year":"2024","unstructured":"Hurtado I, Robles C, Peir\u00f3 S, Garc\u00eda-Sempere A, Sanf\u00e9lix-Gimeno G. Association of glucagon-like peptide-1 receptor agonists with suicidal ideation and self-injury in individuals with diabetes and obesity: a propensity-weighted, population-based cohort study. Diabetologia. 2024. https:\/\/doi.org\/10.1007\/s00125-024-06243-z.","journal-title":"Diabetologia"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02836-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-02836-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02836-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T12:33:39Z","timestamp":1760358819000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-025-02836-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2836"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-02836-5","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"assertion":[{"value":"12 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol was reviewed and approved by \u201cScientific Research Assessment and Ethics Committee of Ankara Etlik City Hospital\u201d on January 31, 2024, with the approval number AE\u015eH-BADEK-2024-101.\u00a0\u00a0Informed consent was obtained from participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"956"}}